#METABOLOMICS WORKBENCH kconge2_20240617_174608 DATATRACK_ID:4936 STUDY_ID:ST003306 ANALYSIS_ID:AN005417 PROJECT_ID:PR002056 VERSION 1 CREATED_ON July 9, 2024, 12:26 pm #PROJECT PR:PROJECT_TITLE ASCT2 is a major contributor to serine uptake in cancer cells PR:PROJECT_TYPE GCMS quantitative analysis PR:PROJECT_SUMMARY Polar metabolite abundance studies from MCF7 human ER+ breast cancer cell line PR:PROJECT_SUMMARY with or without CRISPR-Cas9 knockout of ASCT2. Studies used RPMI media with PR:PROJECT_SUMMARY either complete serine levels (285uM), low serine levels (50uM), or no PR:PROJECT_SUMMARY glutamine. PR:INSTITUTE University of Illinois Chicago PR:DEPARTMENT Physiology and Biophysics PR:LABORATORY Coloff Lab PR:LAST_NAME Conger PR:FIRST_NAME Kelly PR:ADDRESS 909 S Wolcott Ave, Chicago, IL, 60612 PR:EMAIL kconge2@uic.edu PR:PHONE 2314320406 #STUDY ST:STUDY_TITLE ASCT2 is a major contributor to serine uptake in cancer cells ST:STUDY_SUMMARY The non-essential amino acid serine is a critical nutrient for cancer cells due ST:STUDY_SUMMARY to its diverse biosynthetic functions. While some tumors can synthesize serine ST:STUDY_SUMMARY de novo, others are auxotrophic and therefore reliant on serine uptake. ST:STUDY_SUMMARY Importantly, despite several transporters being known to be capable of ST:STUDY_SUMMARY transporting serine, the transporter(s) that mediate serine uptake in cancer ST:STUDY_SUMMARY cells are not known. Here, we characterize the amino acid transporter ASCT2 ST:STUDY_SUMMARY (SLC1A5) as a major contributor to serine uptake in cancer cells. ASCT2 is ST:STUDY_SUMMARY well-known as a glutamine transporter in cancer, and our work demonstrates that ST:STUDY_SUMMARY serine and glutamine compete for uptake through ASCT2. We further show that ST:STUDY_SUMMARY ASCT2-mediated serine uptake is essential for purine nucleotide biosynthesis and ST:STUDY_SUMMARY that ERα promotes serine uptake by directly activating SLC1A5 transcription. ST:STUDY_SUMMARY Together, our work defines an additional important role for ASCT2 as a serine ST:STUDY_SUMMARY transporter in cancer and evaluates ASCT2 as a potential therapeutic target. ST:INSTITUTE University of Illinois Chicago ST:DEPARTMENT Physiology and Biophysics ST:LABORATORY Coloff Lab ST:LAST_NAME Conger ST:FIRST_NAME Kelly ST:ADDRESS 909 S Wolcott Ave, Chicago, IL, 60612 ST:EMAIL kconge2@uic.edu ST:PHONE 2314320406 #SUBJECT SU:SUBJECT_TYPE Cultured cells SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 SU:GENDER Female SU:CELL_STRAIN_DETAILS MCF7 SU:CELL_PRIMARY_IMMORTALIZED Immortalized #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS sgLuc IM 1 sgLuc IM 1 Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:50uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgLuc IM 1.D SUBJECT_SAMPLE_FACTORS sgLuc IM 2 sgLuc IM 2 Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:50uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgLuc IM 2.D SUBJECT_SAMPLE_FACTORS sgLuc IM 3 sgLuc IM 3 Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:50uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgLuc IM 3.D SUBJECT_SAMPLE_FACTORS sgSLC1A5-1 IM 1 sgSLC1A5-1 IM 1 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-1 IM 1.D SUBJECT_SAMPLE_FACTORS sgSLC1A5-1 IM 2 sgSLC1A5-1 IM 2 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-1 IM 2.D SUBJECT_SAMPLE_FACTORS sgSLC1A5-1 IM 3 sgSLC1A5-1 IM 3 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-1 IM 3.D SUBJECT_SAMPLE_FACTORS sgSLC1A5-3 IM 1 sgSLC1A5-3 IM 1 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-3 IM 1.D SUBJECT_SAMPLE_FACTORS sgSLC1A5-3 IM 2 sgSLC1A5-3 IM 2 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-3 IM 2.D SUBJECT_SAMPLE_FACTORS sgSLC1A5-3 IM 3 sgSLC1A5-3 IM 3 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-3 IM 3.D SUBJECT_SAMPLE_FACTORS Luc Puro 1 Luc Puro 1 Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:285uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgLuc Puro 1.D SUBJECT_SAMPLE_FACTORS Luc Puro 2 Luc Puro 2 Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:285uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgLuc Puro 2.D SUBJECT_SAMPLE_FACTORS Luc Puro 3 Luc Puro 3 Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:285uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgLuc Puro 3.D SUBJECT_SAMPLE_FACTORS SLC1A5-1,1 SLC1A5-1,1 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:285uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-1,1.D SUBJECT_SAMPLE_FACTORS SLC1A5-1,2 SLC1A5-1,2 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:285uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-1,2.D SUBJECT_SAMPLE_FACTORS SLC1A5-1,3 SLC1A5-1,3 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:285uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-1,3.D SUBJECT_SAMPLE_FACTORS SLC1A5-3,1 SLC1A5-3,1 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:285uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-3,1.D SUBJECT_SAMPLE_FACTORS SLC1A5-3,2 SLC1A5-3,2 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:285uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-3,2.D SUBJECT_SAMPLE_FACTORS SLC1A5-3,3 SLC1A5-3,3 Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:285uM Serine Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgSLC1A5-3,3.D SUBJECT_SAMPLE_FACTORS sgLuc -Q 60 1 sgLuc -Gln 60 1 Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:(-Gln)1hr Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgLuc -Q 60 1.D SUBJECT_SAMPLE_FACTORS sgLuc -Q 60 2 sgLuc -Gln 60 2 Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:(-Gln)1hr Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgLuc -Q 60 2.D SUBJECT_SAMPLE_FACTORS sgLuc -Q 60 3 sgLuc -Gln 60 3 Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:(-Gln)1hr Cell line=MCF7; RAW_FILE_NAME(Raw_File_Name)=sgLuc -Q 60 3.D #COLLECTION CO:COLLECTION_SUMMARY Cells were washed with PBS and fed media containing either complete serine CO:COLLECTION_SUMMARY (285uM) or low serine (50uM) for six hours. Cells were washed with saline and CO:COLLECTION_SUMMARY harvested in cold GCMS-grade methanol with norvaline diluted in water. Polar CO:COLLECTION_SUMMARY metabolites were extracted with the addition of chloroform. Samples were dried CO:COLLECTION_SUMMARY under constant air flow for 2 hours. CO:COLLECTION_PROTOCOL_FILENAME CL_PM2024.pdf CO:SAMPLE_TYPE Cultured cells CO:STORAGE_CONDITIONS -80℃ #TREATMENT TR:TREATMENT_SUMMARY Cells are either control (sgLuc) or ASCT2-KO (sgSLC1A5). All groups were plated TR:TREATMENT_SUMMARY in triplicate in a six well plate 48hours prior to treatment. Cells were treated TR:TREATMENT_SUMMARY with either complete media, or media containing low serine for six hours, or TR:TREATMENT_SUMMARY media lacking glutamine (-Q) for one hour prior to harvesting. TR:TREATMENT_DOSEDURATION 1-6 hours TR:CELL_GROWTH_CONTAINER Corning 6-well plates TR:CELL_MEDIA RPMI w/o Glucose, Sodium Pyruvate, Amino acids TR:CELL_PCT_CONFLUENCE 80% #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Samples were harvested in cold GCMS-grade methanol with norvaline diluted in SP:SAMPLEPREP_SUMMARY water. Polar metabolites were separated with chloroform and air dried for two SP:SAMPLEPREP_SUMMARY hours. Samples were then rehydrated in 15uL MOX reagent and heated at 37C for 90 SP:SAMPLEPREP_SUMMARY minutes. Then 20uL of TBDMS was added to each sample and heated at 60C for 60 SP:SAMPLEPREP_SUMMARY minutes. SP:SAMPLEPREP_PROTOCOL_FILENAME CL_PM2024.pdf #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY All samples were analyzed by GC/MS using a HP-5MS Ultra Inert GC column CH:CHROMATOGRAPHY_SUMMARY (19091S-433UI, Agilent Technologies) installed in an Agilent 7890B gas CH:CHROMATOGRAPHY_SUMMARY chromatograph coupled to an Agilent 5779B mass spectrometer. Helium was used as CH:CHROMATOGRAPHY_SUMMARY the carrier gas. One microliter was injected (split inlet) at 280 degrees C. CH:CHROMATOGRAPHY_SUMMARY After injection, the GC oven was held at 60 degrees C for 1 minute before CH:CHROMATOGRAPHY_SUMMARY ramping to 320 degrees C at 10C/min and held for 9 minutes at the maximum CH:CHROMATOGRAPHY_SUMMARY temperature. CH:CHROMATOGRAPHY_TYPE GC CH:INSTRUMENT_NAME Agilent 7890B CH:COLUMN_NAME Agilent HP5-MS (30m x 0.25mm, 0.25 um) CH:SOLVENT_A N/A CH:SOLVENT_B N/A CH:FLOW_GRADIENT N/A CH:FLOW_RATE 1.5mL/min CH:COLUMN_TEMPERATURE 60-320 #ANALYSIS AN:ANALYSIS_TYPE MS AN:ANALYSIS_PROTOCOL_FILE CL_GCMS2024.pdf #MS MS:INSTRUMENT_NAME Agilent 5977B MS:INSTRUMENT_TYPE Single quadrupole MS:MS_TYPE EI MS:ION_MODE POSITIVE MS:MS_COMMENTS The MS system operated under electron impact ionization mode at 70 eV and the MS MS:MS_COMMENTS source and quadrupole were held at 230 degrees C and 150 degrees C respectively. MS:MS_COMMENTS Peak areas were determined using MassHunter software. #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS Abundance MS_METABOLITE_DATA_START Samples sgLuc IM 1 sgLuc IM 2 sgLuc IM 3 sgSLC1A5-1 IM 1 sgSLC1A5-1 IM 2 sgSLC1A5-1 IM 3 sgSLC1A5-3 IM 1 sgSLC1A5-3 IM 2 sgSLC1A5-3 IM 3 Factors Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:50uM Serine Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:50uM Serine Sample source:Human breast cancer cells | Genotype:Ctrl | Treatment:50uM Serine Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Sample source:Human breast cancer cells | Genotype:ASCT2-KO | Treatment:50uM Serine Norvaline 2697956 2303871 2267103 2524417 2202538 2289605 2484960 2364121 2281996 alpha-Ketoglutarate 10402 9888 9045 12673 9879 9472 11535 10254 10696 Aspartic Acid 423133 360546 344866 543128 476509 488161 609948 633544 559695 Citrate 36286 33583 32984 41730 34157 32315 44951 46076 42901 Citrulline 22268 20484 18261 15692 16168 17232 25030 15556 17513 Lactate 408296 409663 374741 341478 327207 292581 275397 275653 246223 L-Alanine 55694 51416 54068 129416 113097 112447 179333 187351 166781 L-Asparagine 346175 223916 205439 336078 272295 340272 484522 478085 374410 L-Cysteine 59575 38504 25806 27131 21751 24296 66706 50354 37462 L-Glutamate 1385417 1274150 1304122 1520223 1355443 1369860 1583715 1622297 1503952 L-Glutamine 1359422 1019394 952235 1149413 1107747 1085512 1501513 1523635 1164320 L-Glycine 298081 257184 263677 401319 339651 349507 413485 422620 387013 L-Isoleucine 713472 631024 577792 563223 495352 490266 688394 654675 596315 L-Leucine 792415 675603 640348 614344 550546 533982 758907 729609 648271 L-Lysine 21349 18126 17151 18113 15645 14640 23380 21443 18667 L-Methionine 80701 68333 63686 62289 54426 52746 73948 69724 63768 L-Phenylalanine 45170 37035 35797 34580 29476 28738 43748 40777 37147 L-Proline 63477 48227 49467 61301 59238 60450 73633 73136 64207 L-Serine 34549 28552 30886 22857 19633 20472 18978 15975 15181 L-Threonine 62029 48035 50976 40977 42288 51692 46303 51378 37526 L-Tyrosine 68229 61794 60444 55204 48238 48572 70472 66103 60378 L-Valine 270634 236044 222593 204315 183767 177932 266505 252465 224866 Malate 132722 120344 123263 143788 129266 128085 122554 126028 119490 OH-Proline 60748 55818 63224 63300 68379 76312 86080 99550 89039 Pyruvate 126663 112897 102740 111891 97328 93330 130419 117918 102525 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name PubChem ID Norvaline 65098 alpha-Ketoglutarate 51 Aspartic Acid 5960 Citrate 31348 Citrulline 9750 Lactate 91435 L-Alanine 5950 L-Asparagine 6267 L-Cysteine 5862 L-Glutamate 33032 L-Glutamine 5961 L-Glycine 750 L-Isoleucine 6306 L-Leucine 6106 L-Lysine 5962 L-Methionine 6137 L-Phenylalanine 6140 L-Proline 145742 L-Serine 5951 L-Threonine 6288 L-Tyrosine 6057 L-Valine 6287 Malate 525 OH-Proline 614 Pyruvate 107735 METABOLITES_END #END